Gastrointestinal stromal tumour (GIST) - adjuvant

The Pharmaceutical Benefits Scheme subsidises imatinib mesylate for patients with resected primary gastrointestinal stromal tumour with high risk of recurrence.

The Pharmaceutical Benefits Scheme subsidises imatinib mesylate for patients with resected primary gastrointestinal stromal tumour (GIST) with high risk of recurrence.

For patients with completely resected primary gastrointestinal stromal tumour with a high risk of recurrence, treatment with imatinib mesylate (Glivec®) can be subsidised through the Pharmaceutical Benefits Scheme (PBS), under section 85 of the National Health Act 1953.

Restriction details

The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing imatinib mesylate.

Initial treatment

Up to five repeats will be authorised for an initial application.

Continuing treatment

Authority approval for continuing treatment may be requested in writing, send written applications to the Complex drugs address on the contact us page or may be obtained by contacting us on the Complex Drug Enquiry line.

Schedule item details

Dose - The treatment must not exceed a dose of 400 mg per day for a period of 36 months in total.

Glivec® is available in tablet form:

  • Glivec 100 mg tablets in a pack size of 60 and
  • Glivec 400 mg tablets in a pack size of 30

Patient eligibility

Patients must meet the relevant criteria as indicated in the restrictions and be eligible for the Pharmaceutical Benefits Scheme.

Reports

The following reports are required for initial PBS subsidised applications:

A copy of pathology report(s) from an approved Australian pathology authority confirming:

  • the diagnosis of a gastrointestinal stromal tumour
  • the presence of CD117 on immunohistochemical staining
  • the size and mitotic rate of the tumour
  • the date of tumour resection, which must not be more than three months prior to the date of the initial application

Lodging an application

All initial application requests must be made in writing. Send all written applications to the Complex drugs address on the contact us page. Authority approval for continuing treatment may be requested in writing or may be obtained by contacting us on the Complex Drugs enquiry line.

Further information

For more information contact us on the Complex Drugs enquiry line.

Page last updated: 27 January 2016

This information was printed Friday 9 December 2016 from humanservices.gov.au/health-professionals/enablers/gastrointestinal-stromal-tumour-gist-adjuvant It may not include all of the relevant information on this topic. Please consider any relevant site notices at humanservices.gov.au/siteinformation when using this material.